查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961245

過敏護理市場－全球產業規模、佔有率、趨勢、機會和預測：按類型、療法、分銷管道、地區和競爭格局分類，2021-2031年

Allergy Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球過敏護理市場預計將從 2025 年的 238.7 億美元大幅成長至 2031 年的 379.1 億美元，複合年成長率為 8.01%。

該領域涵蓋多種診斷方法、藥物干預和免疫療法，旨在檢測和治療由環境、藥物和食物過敏原引起的免疫超敏反應。推動這一領域發展的關鍵因素包括：快速都市化導致過敏性疾病盛行率上升、污染加劇以及全球飲食結構變化。此外，大眾對早期診斷和有效治療重要性的認知不斷提高，也推動了處方藥和非處方治療方法的需求。氣喘與過敏基金會的數據凸顯了這項負擔，並預測到2025年，美國每年將有超過1億人遭受各種過敏症的困擾。

市場概覽
預測期 2027-2031
市場規模：2025年 238.7億美元
市場規模：2031年 379.1億美元
複合年成長率：2026-2031年 8.01%
成長最快的細分市場 抗過敏藥物
最大的市場 北美洲

儘管市場需求強勁，先進療法的高成本是限制行業擴張的主要障礙。複雜的診斷測試和長期免疫療法的巨額費用限制了相當一部分人群，特別是開發中國家的治療機會。這種經濟障礙有效地阻礙了綜合過敏治療方法的廣泛應用。因此，治療費用的可負擔性仍然是一個重大挑戰，可能會因為將無力承擔這些昂貴醫療干預措施的潛在患者排除在外而抑制全球過敏治療行業的預期成長。

市場促進因素

免疫療法的創新和新型生物製藥的出現正在改變全球過敏症的治療格局，將臨床重點從暫時的症狀管理轉向長期的緩解疾病和脫敏治療。近期出現的生物目標為重度IgE介導的食物過敏患者提供了一種突破性的治療選擇，這些患者先前只能依靠迴避策略。例如，基因泰克公司在2024年2月發布的新聞稿中提到，FDA核准了其產品Zoria上市，並指出在III期OUTMATCH試驗中，67%的受試者能夠單次服用600毫克花生蛋白而未出現中度至重度症狀。這種提高過敏反應閾值的能力正在推動高價值處方箋的普及，並隨著醫療機構將這些先進治療方法納入標準治療通訊協定，擴大了該行業的商業性前景。

此外，快速的都市化和環境污染正在成為市場催化劑，而氣候變遷則增加了過敏原暴露，延長了呼吸道過敏季節。全球暖化導致植物提早開花，花粉濃度升高，使得更多人需要持續治療。根據哥倫比亞廣播公司新聞網2024年4月報道，美國國家生物物候網路的數據顯示，底特律等主要城市的春季比往年提早了23天。這種環境變化顯著提升了大型製藥公司的收益，同時也帶來了需求的激增。賽諾菲在2024年報告稱，其旗艦免疫療法藥物Dupixent第二季度的銷售額成長了29.2%，達到33.03億歐元。

市場挑戰

高昂的專業診斷和長期免疫療法費用仍然是全球過敏治療市場成長的主要障礙。儘管過敏症的發生率持續上升，但綜合治療的高昂費用限制了全球相當一部分人口獲得治療的機會。這種經濟障礙在開發中國家和未投保者人群中尤其嚴重，導致他們往往選擇價格低廉的短期症狀治療，而不是必要的疾病管理。因此，該行業在將潛在患者群體轉化為可靠的收入來源方面面臨挑戰，限制了在價格敏感型市場中治療服務的擴充性。

這種經濟差距的嚴重性從患者經濟負擔的統計中可見一斑。根據歐洲過敏與臨床免疫學會的報告，預計到2025年，每位過敏性疾病患者的平均年度總費用將達到1,329.55歐元。如此沉重的經濟負擔阻礙了永續治療方案的廣泛應用。因此，這些經濟限制直接限制了該行業最大限度地發揮其成長潛力，並深化在不同地區的市場滲透。

市場趨勢

全球過敏治療市場正經歷舌下免疫療法 (SLIT) 的重大轉變，SLIT 已成為傳統皮下注射療法的替代方案。這一趨勢的特徵是標準化過敏原片劑的日益普及，患者可以在家中自行服用，有效避免了頻繁就醫和注射的麻煩。這種向非侵入性治療的轉變，透過提高患者依從性和便利性，擴大了呼吸道過敏治療的潛在市場。近期財務表現也印證了此方法的商業性可行性。根據 ALK-Abello 於 2025 年 2 月發布的 2024 年年度報告，受歐洲市場銷售成長和價格調整的推動，片劑銷售額成長了 24%，達到 28.51 億丹麥克朗。

與此同時，數位醫療和遠距過敏諮詢平台的興起正在改變醫療服務模式，彌合了專科醫生和患者之間的就醫鴻溝。醫療服務提供者正日益利用整合的數位生態系統，透過電子諮詢和遠距分診來簡化患者就診流程，並將離線資源優先用於複雜、高風險病例。這種數位化轉型提高了臨床效率，使過敏性疾病的管理無需患者親自到場，並克服了基礎設施的限制。臨床數據也支持了這項轉型的成功。根據發表在2024年4月《過敏前沿》（Frontiers in Allergy）雜誌上的一篇文章，2023年，來自基層醫療的電子諮詢中有42.8%無需患者親自到場即可成功解決。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球過敏護理市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（眼睛過敏、鼻炎、氣喘、皮膚過敏、食物過敏、其他過敏）
    • 治療方法（抗組織胺、免疫療法）
    • 分銷通路（醫院、網路藥局、零售藥局、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美過敏護理市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲過敏護理市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區過敏護理市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲過敏護理市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲過敏護理市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球過敏護理市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • ALK-Abello A/S
  • AbbVie Inc.
  • Allergy Therapeutics PLC
  • Bausch Health Companies Inc.
  • Alembic Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd
  • Nicox SA
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • LETI Pharma, SLU

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24134

The Global Allergy Care Market is projected to experience substantial growth, rising from a valuation of USD 23.87 Billion in 2025 to USD 37.91 Billion by 2031, reflecting a CAGR of 8.01%. This sector encompasses a wide array of diagnostics, pharmaceutical interventions, and immunotherapies aimed at detecting and treating immune hypersensitivities caused by environmental, pharmaceutical, or dietary allergens. Key factors propelling this expansion include the escalating prevalence of allergic conditions due to rapid urbanization, increasing pollution levels, and global changes in dietary patterns. Additionally, growing public awareness regarding the importance of early diagnosis and effective management is boosting the demand for both prescription and over-the-counter treatments. Data from the Asthma and Allergy Foundation of America highlights this burden, noting that in 2025, over 100 million people in the United States suffer from various allergies annually.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 23.87 Billion
Market Size 2031USD 37.91 Billion
CAGR 2026-20318.01%
Fastest Growing SegmentAnti-Allergy Drugs
Largest MarketNorth America

Despite strong market demand, high costs associated with advanced care present a major hurdle to industry expansion. The substantial expense of sophisticated diagnostic testing and long-duration immunotherapy regimens limits accessibility for a significant segment of the population, particularly within developing countries. This economic barrier effectively restricts the widespread adoption of comprehensive allergy solutions. Consequently, affordability remains a critical challenge that threatens to impede the anticipated growth trajectory of the global allergy care sector by excluding potential patients who cannot afford these premium medical interventions.

Market Driver

Innovations in immunotherapy and the emergence of novel biologics are transforming the global allergy care landscape by moving clinical focus from temporary symptom management to long-term disease modification and desensitization. The recent debut of targeted biological therapies has offered revolutionary alternatives for patients with severe IgE-mediated food allergies who previously depended entirely on avoidance strategies. For instance, a February 2024 press release from Genentech regarding the FDA approval of Xolair reported that 67% of Phase III OUtMATCH study participants could safely ingest a single 600 mg dose of peanut protein without experiencing moderate to severe symptoms. This capacity to elevate reaction thresholds is fueling the uptake of high-value prescriptions, broadening the sector's commercial prospects as healthcare providers adopt these advanced regimens into standard protocols.

Furthermore, rapid urbanization and environmental pollution act as substantial market catalysts, with climate change intensifying allergen exposure and prolonging respiratory allergy seasons. Rising global temperatures are triggering earlier plant blooming and higher pollen concentrations, necessitating continuous medical treatment for a broader demographic. A CBS News report from April 2024 noted that data from the USA National Phenology Network showed spring conditions arriving up to 23 days earlier than usual in major cities like Detroit. This environmental shift is driving significant revenue increases for leading pharmaceutical companies as demand escalates; Sanofi reported in 2024 that second-quarter sales of its blockbuster immunology drug Dupixent rose by 29.2% to reach €3,303 million.

Market Challenge

The prohibitive expense of specialized diagnostics and long-term immunotherapy remains a primary obstruction to the growth of the Global Allergy Care Market. While the incidence of hypersensitivities continues to climb, the steep costs attached to comprehensive care limit access for a vast portion of the global population. This financial hurdle is especially severe in developing countries and among uninsured groups, where individuals frequently opt for inexpensive, temporary symptomatic relief instead of necessary disease management. As a result, the industry faces difficulties in converting a high volume of potential patients into reliable revenue sources, which constrains the scalability of therapeutic offerings in price-sensitive markets.

The severity of this affordability gap is highlighted by statistical evidence regarding the financial burden on patients. According to reports from the European Academy of Allergy and Clinical Immunology, the average total cost per patient per year for allergic diseases was estimated at €1,329.55 in 2025. This substantial financial demand impedes the widespread uptake of sustained treatment plans. Consequently, these economic constraints directly hinder the industry's capacity to maximize its growth potential and achieve deeper market penetration across diverse global regions.

Market Trends

The Global Allergy Care Market is undergoing a significant transition toward Sublingual Immunotherapy (SLIT) as a favored alternative to conventional subcutaneous injections. This trend is defined by the growing uptake of standardized allergen tablets, which enable patients to self-administer disease-modifying therapies at home, effectively removing the logistical challenges associated with frequent clinic visits for shots. This move toward non-invasive care is broadening the addressable market for respiratory allergies by enhancing patient adherence and convenience. The commercial viability of this approach is evident in recent financial results; ALK-Abello's 2024 annual report, released in February 2025, indicated that tablet sales rose by 24% to DKK 2,851 million, fueled by increased volume and better pricing in European markets.

Simultaneously, the emergence of Digital Health and Tele-Allergy Platforms is transforming service delivery by closing the accessibility gap between specialists and patients. Providers are increasingly utilizing integrated digital ecosystems that leverage electronic consultations and remote triage to regulate patient flow, ensuring in-person resources are prioritized for complex, high-risk cases. This digital evolution enhances clinical efficiency and enables the management of allergic conditions without requiring physical attendance, thereby overcoming infrastructure limitations. The operational success of this shift is supported by clinical data; an April 2024 article in Frontiers in Allergy reported that 42.8% of electronic consultations originated from primary care in 2023 were resolved successfully without necessitating a face-to-face appointment.

Key Market Players

  • ALK-Abello A/S
  • AbbVie Inc.
  • Allergy Therapeutics PLC
  • Bausch Health Companies Inc.
  • Alembic Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd
  • Nicox SA
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • LETI Pharma, S.L.U

Report Scope

In this report, the Global Allergy Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Care Market, By Type

  • Eye Allergy
  • Rhinitis
  • Asthma
  • Skin Allergy
  • Food Allergies
  • Other Allergies

Allergy Care Market, By Treatment

  • Anti-Allergy Drugs
  • Immunotherapy

Allergy Care Market, By Distribution Channel

  • Hospital
  • Online Pharmacies
  • Retail Pharmacies
  • Others

Allergy Care Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Care Market.

Available Customizations:

Global Allergy Care Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Care Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergies, Other Allergies)
    • 5.2.2. By Treatment (Anti-Allergy Drugs, Immunotherapy)
    • 5.2.3. By Distribution Channel (Hospital, Online Pharmacies, Retail Pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Allergy Care Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Allergy Care Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Allergy Care Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Allergy Care Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Distribution Channel

7. Europe Allergy Care Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Allergy Care Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Allergy Care Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Allergy Care Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Allergy Care Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Allergy Care Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Allergy Care Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Allergy Care Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Allergy Care Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Allergy Care Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Allergy Care Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Allergy Care Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Allergy Care Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Allergy Care Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Allergy Care Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Allergy Care Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Distribution Channel

10. South America Allergy Care Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Allergy Care Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Allergy Care Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Allergy Care Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Allergy Care Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. ALK-Abello A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie Inc.
  • 15.3. Allergy Therapeutics PLC
  • 15.4. Bausch Health Companies Inc.
  • 15.5. Alembic Pharmaceuticals Limited
  • 15.6. F. Hoffmann-La Roche Ltd
  • 15.7. Nicox SA
  • 15.8. GlaxoSmithKline PLC
  • 15.9. Johnson & Johnson
  • 15.10. LETI Pharma, S.L.U

16. Strategic Recommendations

17. About Us & Disclaimer